| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435219000 |
Proteinase
| 223 |
| 435214000 |
Thrombin
| 8 |
| 435217000 |
Plasmin (i.e., fibrinolysin)
| 6 |
| 435213000 |
Trypsin; chymotrypsin | 5 |
| 20090130736 | PRETREATMENT METHOD FOR EXTRACTION OF NUCLEIC ACID FROM BIOLOGICAL SAMPLES AND KITS THEREFOR - The present invention relates to methods for pretreating biological samples for extraction of nucleic acid therefrom. The present invention employs a combination of at least one protein denaturant with one or more of the following elements to form a reaction mixture for extraction of nucleic acid: (1) at least one aprotic solvent, (2) stepwise heating, and (3) sample dilution. | 05-21-2009 |
| 20090269830 | Culture System and Method for Propagation of Human Blastocyst-Derived Stem Cells - The present invention relates to a culture system for and a method for propagation of human blastocyst-derived stem cells (hBS cells) upon enzymatic dissociation into a single cell suspension. The culture system for propagation of human blastocyst-derived stem (hBS) cells comprises
| 10-29-2009 |
| 20120142075 | Microbial Trypsin Mutants having Chymotrypsin Activity And Nucleic Acids Encoding Same - The present invention relates to microbial trypsin variants having chymotrypsin-like activity, comprising: (a) a one or more substitutions corresponding to positions 144, S193, 198, 201, 218, 223, 227, 228, 229, 230, and 231 of amino acids 25 to 248 of SEQ ID NO: 2, (b) one or more deletions corresponding to positions 192, 197, and 226 of amino acids 25 to 248 of SEQ ID NO: 2; and (c) an insertion between positions corresponding to positions 224 and 225 of amino acids 25 to 248 of SEQ ID NO: 2. The present invention further relates to nucleotide sequences encoding microbial trypsin variants having chymotrypsin-like activity; nucleic acid constructs, expression vectors, and recombinant host cells comprising such nucleotide sequences; and methods of producing microbial trypsin variants having chymotrypsin-like activity or a precursor thereof. | 06-07-2012 |
| 20130078705 | PROTEASE FOR TREATING NAIL ABNORMALITIES - A protease for treating nail abnormalities is a type of protease. Since nails are mostly composed of keratin protein, the optimum protease for decomposing the main component (keratin) of the nail is keratinase or serine protease which is functionally similar to keratinase. The serine protease include trypsin, chymotrypsin, elastase, subtilisin, etc, these enzymes can be used to treat pathologically or mechanically damaged nail tissue to thin or remove keratin which is the key component of the nail, thus facilitating drug delivery in later treatment. | 03-28-2013 |
| 20140335594 | Method for the Removal of Virus From a Protein Solution - The present invention relates to a method for selectively removing virus and/or virus DNA from a solution comprising a target protein, whereby acetone is used as a precipitation agent to precipitate virus and/or virus DNA as well as the target protein. | 11-13-2014 |
| 435218000 |
Elastase | 2 |
| 20110081705 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | 04-07-2011 |
| 20150322420 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | 11-12-2015 |
| 435215000 |
Urokinase | 1 |
| 20100055762 | Method for Preparation of Hepatocyte Using Es Cell - This invention relates to an agent for promoting differentiation of an ES cell, preferably an agent for promoting differentiation of an ES cell into a hepatocyte or a prophylactic agent for teratoma, comprising uPA. | 03-04-2010 |
| Entries |
| Document | Title | Date |
|---|
| 20080254527 | VON WILLEBRAND FACTOR (vWF) - CLEAVING PROTEASE - This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura. | 10-16-2008 |
| 20080268521 | Purification of Coagulation Factor VII Polypeptides - An improved method for producing FVII and FVIIa polypeptides is disclosed. Also provided are FVII and FVIIa compositions having low contents of auto-degradation products. | 10-30-2008 |
| 20090068721 | Process for the Production of Recombinant Activated Human Protein C for the Treatment of Sepsis - The present invention relates to a recombinant method of production of activated Protein C. The invention relates to a method of construction, transformation, expression, purification and production of recombinant activated human protein C. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells. | 03-12-2009 |
| 20090142822 | Crystal Structure of an Angiotensin-Converting Enzyme (ACE) and Uses Thereof - The present invention relates to a crystal of ACE protein. The present invention further relates to methods, processes, ACE modulators, pharmaceutical compositions and uses of ACE crystal and the structure coordinates thereof. | 06-04-2009 |
| 20090191608 | Pancreatic Islet Cell Preparation and Transplantation - The present invention includes compositions and methods for the preparation of pancreatic islet cells for transplantation. | 07-30-2009 |
| 20090275105 | PROCESS FOR THE PRODUCTION OF BROMELAIN BY MEANS OF SUBSTANCES THAT INDUCE PROTEINS IN PINEAPPLE PLANTS - Provided are methods of producing, via induction, plant products such as bromelain from plants of the genus | 11-05-2009 |
| 20090325268 | PROLINE-SPECIFIC PROTEASES FREE FROM AMYLOLYTIC ACTIVITIES - The invention relates to a proline-specific protease preparation free from amylolytic activity and a purification method for obtaining the enzyme preparation according to the invention. | 12-31-2009 |
| 20100075396 | Botulinum Neurotoxin Serotype B Activatable Botulinum Neurotoxin Serotype Bs - The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region. | 03-25-2010 |
| 20100081187 | RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME - Methods of isolating highly sialylated recombinant vitamin K dependent proteins, particularly Factor IX, by chromatographic methods are described. The highly sialylated recombinant proteins are characterized. The improved Factor IX has at least 62% N-glycosylation with 3 or 4 sialic acid residues and improved bioavailability and pharmokinetic properties. | 04-01-2010 |
| 20100184188 | Alkaline Protease - It is an object of the present invention to provide alkaline proteases having industrially sufficient protein productivity and a significant detergency. In the alkaline proteases, the amino acid residues at (a) position 9, (b) position 49, (c) position 194, (d) position 212, (e) position 237, (f) position 245, (g) position 281, (h) position 313, (i) position 379 and (j) position 427 in SEQ ID NO: 2 are selected from the following amino acid residues; Position (a); glutamine, Position (b); glutamine, Position (c); lysine or arginine, Position (d); arginine, asparagine or glutamine, Position (e); asparagines, Position (f); asparagines. Position (g); arginine, Position (h); asparagines, Position (i); lysine, arginine, glutamic acid or aspartic acid, and Position (j); arginine. | 07-22-2010 |
| 20100248329 | BLOOD COAGULATION PROMOTER AND BLOOD COLLECTION TUBE - The present invention provides a blood coagulation promoter capable of exerting both excellent blood coagulation promoting ability and excellent blood clot detaching ability, and a blood collection tube accommodating the blood coagulation promoter. The present invention provides a blood coagulation promoter which includes a hardly water soluble polyoxyalkylene derivative; a partially saponificated polyvinyl alcohol; at least one substance selected from the group consisting of adsorptive inorganic substances and hydrolases capable of hydrolyzing a bond between Arg and an arbitrary amino acid reside and/or a bond between Lys and an arbitrary amino acid residue in a peptide chain; a polyvinylpyrrolidone; and preferably a water-soluble silicone oil, and a blood collection tube in which the blood coagulation promoter is accommodated in a tubular vessel having a bottom. | 09-30-2010 |
| 20100285568 | RECOMBINANT FACTOR X WITH NO GLYCOSYLATION AND METHOD FOR PREPARING THE SAME - A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method. | 11-11-2010 |
| 20100297729 | PROCESS FOR PRODUCING TRANSGLUTAMINASE - The present invention relates to a process for secretory production of a foreign protein, in particular, transglutaminase by a coryneform bacterium. | 11-25-2010 |
| 20100330649 | EXPRESSION SYSTEMS FOR FUNCTIONAL MEMBRANE POLYPEPTIDES - Expression systems and methods for the expression of functional membrane polypeptides such as human cytochrome b5 are provided. The systems include recombinant expression vectors capable of expressing soluble fusion proteins that include a solubilizing agent, a linker, and a membrane polypeptide, as well as one or more cleavers, e.g. proteases, capable of cleaving the linker to release the membrane polypeptide. When the fusion protein is expressed, the linker is cleaved by the cleaver to allow association of the membrane polypeptide with a membrane. | 12-30-2010 |
| 20110003363 | Reduction of Dimer Content in Factor VII Polypeptide Compositions by Heat Treatment - The present application relates to a method of reducing the content of dimers in Factor VII polypeptide composition by heat treatment. | 01-06-2011 |
| 20110020900 | LACTOBACILLUS ACIDOPHILUS NUCLEIC ACID SEQUENCES ENCODING PROTEASE HOMOLOGUES AND USES THEREFORE - Protease-like nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, protease-like fusion proteins, antigenic peptides, and anti-protease-like antibodies are encompassed. The invention also provides vectors containing a nucleic acid molecule of the invention and cells into which the vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed. | 01-27-2011 |
| 20110027859 | METHOD FOR PRODUCING AMINOPEPTIDASE - Disclosed is an efficient method for production of aminopeptidase. The method comprises either transforming host bacteria with an aminopeptidase gene and with a neutral protease gene, or transforming some part of host bacteria with an aminopeptidase gene while transforming the other part of the host bacteria with a neutral protease gene, culturing in a medium the hose bacteria transformed with the aminopeptidase gene and with the neutral protease gene, or culturing a mixture of the host bacteria transformed with the aminopeptidase gene and the host bacteria transformed with the neutral protease gene, to let both the aminopeptidase and the neutral protease be expressed, and collecting the aminopeptidase thus produced from the culture mixture. | 02-03-2011 |
| 20110059510 | TRANSGENIC RABBITS PRODUCING HUMAN FACTOR VII - The invention relates to transgenic rabbits that produce human factor VII in their mammary glands. The milk of said transgenic rabbits can be used as a raw material for the production of recombinant human factor VII. | 03-10-2011 |
| 20110086411 | Method of Producing a Polypeptide or Virus of Interest in a Continuous Cell Culture - Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d | 04-14-2011 |
| 20110091958 | Multiply-Substituted Protease Variants - Novel enzyme variants including protease variants derived from the DNA sequences of naturally-occurring or recombinant non-human proteases are disclosed. The variant proteases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant protease to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor protease. Such variant proteases have properties which are different from those of the precursor protease, such as altered wash performance. The substituted amino acid residue correspond to positions 27, 45, 170, 181, 251 and 271 of | 04-21-2011 |
| 20110091959 | Multiply-Substituted Protease Variants - Novel enzyme variants including protease variants derived from the DNA sequences of naturally-occurring or recombinant non-human proteases are disclosed. The variant proteases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant protease to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor protease. Such variant proteases have properties which are different from those of the precursor protease, such as altered wash performance. The substituted amino acid residue correspond to positions 27, 45, 170, 181, 251 and 271 of | 04-21-2011 |
| 20110111479 | Botulinum Neurotoxin Serotype B Activatable Botulinum Neurotoxin Serotype Bs - The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region. | 05-12-2011 |
| 20110124084 | PROTEASES - The invention relates to a novel class of serine proteases of peptidase family S2A or S1E that are stable in the presence of copper (Cu | 05-26-2011 |
| 20110136207 | Mutated Nucleotide Sequences of Batroxobin, Mutated Alpha Factor Secretion Signal Sequence and Processes for Preparing Batroxobin Using the Same - The present invention relates to a batroxobin-encoding nucleotide sequence and/or a mutated α-factor secretion signal sequence, and a vector and a transformant using the same. The batroxobin-encoding nucleotide sequence of this invention exhibits an excellent expression efficiency in yeast, particular | 06-09-2011 |
| 20110143420 | Kit for single oxygen atom incorporation into digested peptides - Optimized enzymatic conditions incorporate a single oxygen atom into digested peptides using a peptidase. The incorporation of a single oxygen atom is especially useful for proteolytic | 06-16-2011 |
| 20110143421 | NOVEL PROTEASE AND USE THEREOF - A novel protease comprising any one of
| 06-16-2011 |
| 20110159571 | ADENOVIRUS TARGETING - This document provides methods and materials involved in targeting adenoviruses. For example, this document provides nucleic acid molecules encoding a γ-carboxylated glutamic acid (GLA) domain of a factor X (fX) polypeptide, polypeptides having a GLA domain of a fX polypeptide, adenoviruses containing such nucleic acid molecules, adenoviruses containing such polypeptides, adenoviruses containing such nucleic acid molecules and such polypeptides, and compositions containing therapeutic adenoviral vectors and polypeptides having a GLA domain of an fX polypeptide. In addition, methods and materials for using adenoviruses as viral vectors to deliver nucleic acid to cells other than hepatocytes in vivo, methods and materials for using adenoviruses as vaccines, and methods and materials for using adenoviruses to treat cancer are provided. | 06-30-2011 |
| 20110177580 | Method of Controlling a Polypeptide Modification Reaction - The invention relates to a method of controlling a polypeptide modification reaction, in particular but not exclusively, a method of controlling the activation of human factor VII (FVII) to produce human factor VII(a) (FVII(a)). The invention also relates to polypeptides obtainable by the polypeptide modification reaction and to pharmaceutical compositions comprising said polypeptides. | 07-21-2011 |
| 20110177581 | Mutant MT-SP1 proteases with altered substrate specificity or activity - MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis. | 07-21-2011 |
| 20110195482 | SERINE PROTEASE ISOLATED FROM THE VENOM OF BOMBUS IGNITUS AS FIBRINOGENOLYTIC AND FIBRINOLYTIC ENZYMES - Disclosed is serine protease isolated from | 08-11-2011 |
| 20110201085 | NUCLEIC ACID EXTRACTION FROM COMPLEX MATRICES - The present disclosure describes an adsorbent and exemplary protocols for extracting nucleic acids, such as DNA and RNA, from complex matrices, such as stool samples and water samples. The adsorbent is activated charcoal coated with a material such as polyvinylpyrrolidone, dextran, or coconut flours. The adsorbent may be used in microcentrifuge spin columns, where it may be present as a slurry in a storage solution. The sample may be prepared by vortexing in a buffer solution, centrifuging, adding a protease to the supernatant, and passing the supernatant through a microcentrifuge spin column containing coated activated charcoal. The key components, including buffer, protease, and spin columns, may be packaged in a kit. | 08-18-2011 |
| 20110244549 | HEPATITIS C VIRUS VARIANTS - The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient. | 10-06-2011 |
| 20110244550 | FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION - Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide. | 10-06-2011 |
| 20110244551 | EXTRACT HAVING PROTEASE ACTIVITY - The present invention discloses a composition comprising a proteinaceous extract of | 10-06-2011 |
| 20110281327 | Compositions And Methods Comprising Variant Proteases - The present invention provides variant proteases, compositions comprising such variant proteases, and methods of cleaning comprising such variant proteases. | 11-17-2011 |
| 20110294191 | INCREASED PRODUCTION OF ASPARTIC PROTEASES IN FILAMENTOUS FUNGAL CELLS - Described are compositions and methods relating to filamentous fungal cells genetically engineered to provide increased production of aspartic proteases, such as PEPAa, PEPAb, PEPAc, and PEPAd. Also described are nucleic acids and methods for making the engineered filamentous fungal cells. | 12-01-2011 |
| 20120225469 | ACID FUNGAL PROTEASES - The present invention is directed to novel acid proteases and more specifically to NSP24 family proteases and NSP25 family proteases including biologically active fragments thereof and to nucleic acid molecules encoding said proteases. Also provided are vectors and host cells including nucleic acid sequences coding for the proteases, methods for producing the proteases, enzyme compositions and methods employing said proteases. | 09-06-2012 |
| 20130034896 | Purification of Blood Coagulation Factors - The present invention relates to the purification of vitamin K-dependent blood coagulation factors, such as Factor IX (FIX). In particular, the invention provides a method for purifying Factor IX having a desired content of gamma-carboxyglutamic acid from a sample comprising a mixture of species of said Factor IX having different contents of gamma-carboxyglutamic acid, said method comprising the steps of: (a) loading said Factor IX sample onto an immunoaffinity chromatography material coupled to a binding moiety for gamma-carboxyglutamic acid; (b) eluting said Factor IX; and (c) selecting a fraction obtained from said elution wherein the polypeptides in the fraction have the desired content of gamma-carboxyglutamic acids; characterised in that the total concentration of Factor IX within said sample exceeds the binding ability of the immunoaffinity chromatography material. | 02-07-2013 |
| 20130203150 | Method for Isolation of Nucleic Acids and a Kit Thereof - The present disclosure provides a method to isolate natural & artificial nucleic acids like deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and peptide nucleic acid (PNA) from a solid or liquid sample using cotton. The cotton packed is such that, a solution containing nucleic acids passes through it and the nucleic acids in solution are bound to the cotton in a medium optimal for binding. The nucleic acids are bound to cotton in such a way that, the bound nucleic acids can withstand multiple washes with liquid comprising water and gets eluted in an aqueous buffer, with which eluted nucleic acids can be directly used for amplification using PCR or for any other biochemical or molecular biology needs. | 08-08-2013 |
| 20130344567 | METHOD FOR IMMOBILISING NUCLEIC LIGANDS - The invention relates to a method for immobilizing nucleic ligands including at least one reactive amine function, by grafting on an activated solid substrate, including a step of coupling said nucleic acids on said activated solid substrate having a pH of less than 6. | 12-26-2013 |
| 20150031114 | DETERGENT COMPOSITIONS COMPRISING SUBTILASE VARIANTS - The present invention relates to detergent compositions comprising subtilisin variants and methods for obtaining such detergent compositions. The present invention also relates to the use of such detergent compositions, especially in laundry or in hard surface cleaning applications. | 01-29-2015 |
| 20150132825 | COMPOSITIONS AND METHODS COMPRISING SERINE PROTEASE VARIANTS - The present invention provides methods for protein engineering and serine protease variants produced there from. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants. | 05-14-2015 |
